Syncona Biotechs Face Up To Trial Delays Over COVID-19

Programs Put Back 'At Least Three Months'

Clinical trials across the board are being impacted by coronavirus and Syncona, the investment powerhouse behind a number of UK cell and gene therapy biotechs, says that its portfolio companies are facing considerable delays.

Delayed
Delays hitting clinical trials across the board • Source: Shutterstock

With the effects of the coronavirus disease spreading across every aspect of health care, UK biotech investment major Syncona has given an update on how COVID-19 is affecting clinical trials at its portfolio companies.

Syncona, founded in 2012 with £250m from the Wellcome Trust, has been fundamental in the founding of a number...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from COVID-19

More from Scrip

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By 

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

In Brief: Opus Gears Up For FDA Filing In Presbyopia

 

Data from a second pivotal trial support a filing in the US for Opus Genetics’ phentolamine ophthalmic solution, to treat presbyopia.

BlissBio Goes Solo On HER2-Targeting ADC After Eisai Exit

 

BlissBio is to single-handedly move BB-1701, its eribulin-containing, HER2-targeting antibody-drug conjugate, into a global pivotal Phase II/III program for HER2-expressing, Enhertu-resistant breast cancer.